Several lines of evidence suggest that some cellular effectors may display a dynamic regulation of Rad51 expression in prostate cancers, including p53, Cdk4 and mitogen-activated protein kinase (MAPK) (35–38). This evidence concerns the gene RAD51 and prostate carcinoma.